Aldesleukin in advanced renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 4, Issue 6, 2004, Pages 957-980

  Schmidinger, Manuela ^a   Hejna, Michael ^a   Zielinski, Christoph C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Aldesleukin; Cytokine; Interleukin 2; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ALPHA1 INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; BETA1 INTERFERON; BEVACIZUMAB; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYTOKINE; ERYTHROPOIETIN; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GAMMA1B INTERFERON; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 6; ISOTRETINOIN; LEVAMISOLE; MEDROXYPROGESTERONE ACETATE; NALTREXONE; RECOMBINANT INTERLEUKIN 2; ROQUINIMEX; TAMOXIFEN; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN; VINBLASTINE;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CAPILLARY LEAK SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL TRIAL; DEPRESSION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG POTENTIATION; DYSPNEA; EOSINOPHILIA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; KIDNEY CARCINOMA; LIVER DYSFUNCTION; LUNG TOXICITY; LYMPHOCYTOSIS; MALAISE; MENTAL DISEASE; METASTASIS; MONOTHERAPY; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 10644237161     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.6.957     Document Type: Review

References (179)

1. Storkel S, Eble JN, Adlakha K et al. Classification of renal cell carcinoma: Working Group No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80, 987-989 (1997).
2. Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327, 721-724 (1987).
3. Linehan WM, Shipley WU, Parkinson DR. Cancer of the kidney and ureter. In Cancer: Principles and Practice of Oncology, DeVita VT, Hellan S, Rosenberg SA (Eds), JB Lippincott, PA, USA, 1023-1051 (1993).
4. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N. Engl. J. Med. 335, 865-875 (1996).
5. Motzer RJ, Russo P, Nanus DM. Current Problems in Cancer: Renal Cell Carcinoma. Mosby, MO, USA 18, 9-232 (1997).
6. Finke JH, Rayman P, Hart L. Characterization of TIL subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, IFN-α secretion and proliferation. J. Immunother. 15, 91-104 (1994).
7. Van den Hove LE, Van Gool SW, Van Poppel H, Coorrevits L, van Damme B, Ceupens JL. Phenotype, cytokine production and cytolytic capacitiy of freh (uncultured) tumor-infiltrating T-lymphocytes in human renal cell carcinoma Clin. Exp. Immunol. 109, 501-509 (1997).
8. Kunische-Hoppe M, Bohle RM, Rauber K et al. Metastatic renal cell carcinoma arising in a transplant kidney. Eur. Radiol. 8, 441-442 (1998).
9. Olivier RTD, Mehta A, Barnett MJ. A Phase II study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression. Mol. Biother. 1, 14-20 (1988).
10. Witt PL, Lindner DJ, D'Ainha J. Pharmacology of interferons: induced proteins, cell activation, and antitumor activity. In: Cancer Chemotherapy and Biotherapy: Principles and Practice. Chabner BA, Longo DL (Eds), Lippencott, Williams and Wilkins, PA, USA, 585-608 (1996).
11. Bukowski RM, McLain D, Finke JF. Clinical pharmacokinetics of interleukin-1, 2, 4, tumor-necrosis factor and macrophade colony-stimulating factor. In: Cancer Chemotherapy and Biotherapy. Principle and Practice. Chabner BA, Longo DL (Eds), Lippencott, Williams and Wilkins, PA, USA, 612-619 (1996).
12. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 193, 1007-1008 (1976).
13. Rubin JT. Interleukin-2: its biology and clinical application in patients with cancer. Cancer Invest. 11(4), 460-472 (1993).
14. Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res. 45(8), 3735-3741 (1985).
15. Young NT, Roelen DL, Dallman MJ, Morris PJ, Welsh KI. HLA-DRB1 amino acid disparity is the major stimulus of interleukin-2 production by alloreactive helper T-lymphocytes. Immunogenetics 47(4), 310-317 (1998).
16. Taniguchi T, Matsui H, Fujita T et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302(5906), 305-310 (1983).
17. Rosenberg SA, Grimm EA, McGrogan M et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 223(4643), 1412-1414 (1984).
18. Jeal W, Goa KL. Aldesleukin (recombinant IL-2): a review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma. Bio. Drugs 7, 285-317 (1997).
19. Buzio C, De Palma G, Passalacqua R et al. Effectiveness of very low doses of immunotherapy in advanced renal cellcancer. Br. J. Cancer 76(4), 541-544 (1997).
20. Pavone L, Andrulli S, Santi R, Majori M, Buzio C. Long-term treatment with low doses of interleukin-2 and interferon-α: immunological effects in advanced renal cell cancer. Cancer Immunol. Immunother. 50(2), 82-86 (2001).
21. Jablons D, Bolton E, Mertins S et al. IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis. J. Immunol. 144(9), 3630-3636 (1990).
22. Whittington R, Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46(3), 446-514 (1993).
23. Oppenheim MH, Lotze MT. Interleukin-2: solid-tumor therapy. Oncology 51(2), 154-169 (1994).
24. Lotze MT, Matory YL, Ettinghausen SE et al. In vivo administration of purified human interleukin-2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J. Immunol. 135(4), 2865-2875 (1985).
25. Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J. Sci. Am. 3(Suppl. 1), S79-S84 (1997).
26. Physicians' Desk Reference. Medical Economic Co., NJ, USA, 894-898 (1999).
27. Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J. Immunol. 130(5), 2203-2208 (1983).
28. Schiphorst PP, Chang PC, Clar N, Schoemaker RC, Osanto S. Pharmacokinetics of interleukin-2 in two anephric patients with metastatic renal cell cancer. Ann. Oncol. 10(11), 1381-1383 (1999 ).
29. Rosenberg SA. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J. Biol. Response Mod. 3(5), 501-511 (1984).
30. Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann. Surg. 208(2), 121-135 (1988).
31. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13(3), 688-696 (1995).
32. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313(23), 1485-1492 (1985).
33. Whitehead RP, Ward D, Hemingway L, Hemstreet GP III, Bradley E, Konrad M. Subcutaneous recombinant interleukin-2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res. 50(20), 6708-6715 (1990).
34. Stein RC, Malkovska V, Morgan S et al. The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 Br. J. Cancer 63(2), 275-278 (1991).
35. Stoter G, Fossa SD, Rugarli C et al. Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre study. Cancer Treat. Rev. 16(Suppl. A), 111-113 (1989).
36. Rosenberg SA, Lotze MT, Yang JC et al. Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol. 7(12), 1863-1874 (1989).
37. Abrams JS, Rayner AA, Wiernik PH et al. High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma. J. Natl Cancer Inst. 82(14), 1202-1206 (1990).
38. Bukowski RM, Goodman P, Crawford ED, Sergi JS, Redman BG, Whitehead RP. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study. J. Natl Cancer Inst. 82(2), 143-146 (1990).
39. von der Maase H, Geertsen P, Thatcher N et al. Recombinant interleukin-2 in metastatic renal cell carcinoma - a European multicentre Phase II study. Eur. J. Cancer 27(12), 1583-1589 (1991).
40. Geertsen PF, Hermann GG, von der Maase H, Steven K. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center Phase II study: J. Clin. Oncol. 10(5), 753-759 (1992).
41. Negrier S, Mercatello A, Bret M et al. Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma. Br. J. Cancer 65(5), 723-726 (1992).
42. Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an out-patient basis. J. Clin. Oncol. 10(7), 1119-1123 (1992).
43. Lopez M, Carpano S, Cancrini A et al. Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced renal cell carcinoma. Ann. Oncol. 4(8), 689-691 (1993).
44. Buter J, Sleijfer DT, van der Graaf WT, de Vries EG, Willemse PH, Mulder NH. A progress report on the out-patient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin. Oncol. 20(6 Suppl. 9), 16-21 (1993).
45. Philip T, Negrier S, Lasset C et al. Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients. Br. J. Cancer 68(5), 1036-1042 (1993).
46. Escudier B, Ravaud A, Fabbro M et al. High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter study. J. Immunother. Emphasis Tumor Immunol. 16(4), 306-312 (1994).
47. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271(12), 907-913 (1994).
48. Vlasveld LT, Horenblas S, Hekman A et al. Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann. Oncol. 5(2), 179-181 (1994).
49. Gore ME, Galligioni E, Keen CW et al. The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2. Eur. J. Cancer 30A(3), 329-333 (1994).
50. Taneja SS, Pierce W, Figlin R, Belldegrun A Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment. Urology 45(6), 911-924 (1995).
51. Whitehead RP, Wolf MK, Solanki DL et al. A Phase II trial of continuous-infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. J. Immunother. Emphasis Tumor Immunol. 18(2), 104-114 (1995).
52. Escudier B, Farace F, Theodore C et al. Treatment of metastatic kidney neoplasms with a new interleukin-2 protocol: the experience of the Gustave-Roussy Institute. Bull. Cancer 82(4), 296-302 (1995).
53. Tourani JM, Lucas V, Mayeur D et al. Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial. Ann. Oncol. 7(5), 525-528 (1996).
54. Nieken J, Sleijfer DT, Buter J et al. A Phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma. J. Cancer Res. Clin. Oncol. 125(2), 101-108 (1999).
55. Dillman RO, Wiemann MC, VanderMolen LA, Bury MJ, DePriest C, Church C. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: a Phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group). Cancer Biother. Radiopharm. 12(4), 249-255 (1997).
56. Oleksowicz L, Dutcher JP. A Phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma. J. Cancer Res. Clin. Oncol. 125(2), 101-108 (1999).
57. Escudier B, Chevreau C, Lasset C et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d'Immunotherape. J. Clin. Oncol. 17(7), 2039-2043 (1999).
58. Bordin V, Giani L, Meregalli S et al. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. Urol Int. 64(1), 3-8 (2000).
59. Gitlitz BJ, Hoffman DM, Moldawer N, Belldegrun A, Figlin RA. Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients. Cancer J. 7(2), 112-120 (2001).
60. Lissoni P, Bordin V, Vaghi M et al. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2. Anticancer Res. 22(2B), 1061-1064 (2002).
61. Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J. Sci. Am. 3(Suppl. 1), S79-S84 (1997).
62. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21(16), 3127-3132 (2003).
63. Lissoni P. Effects of low-dose recombinant interleukin-2 in human malignancies Cancer J. Sci. Am. 3(Suppl. 1), S115-S120 (1997).
64. Dutcher JP. Interleukin-2 based therapy for kidney cancer. Cancer Treat Res. 116, 155-172 (2003).
65. Margolin K, Rayner AA, Hawkins M. Toxicity of Interleukin-2 and lymphokine-activated killer (LAK) cell therapy. J. Clin. Oncol. 7, 486-489 (1989).
66. Belldegrun A, Webb DE, Austin HA III et al. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann. Intern. Med. 106, 817-822 (1987).
67. Dutcher J, Atkins MB, Margolin K et al. Kidney cancer: the Cytokine Working Group experience (1986-2001). Part II: management of IL-2 toxicity and studies with other cytokines. Med Oncol. 18, 209-219 (2001).
68. Locker GJ, Kapiotis S, Veitl M et al. Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. Br. J. Haematol. 105(4), 912-919 (1999).
69. Cormier JN, Hurst R, Vasselli J et al. A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2. J. Immunother. 20(4), 292-300 (1997).
70. Kim H, Rosenberg SA, Steinberg SM, Cole DJ, Weber JS. A randomized double-blinded comparison of the anti-emetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. J. Immunother. Emphasis Tumor Immunol. 16(1), 60-65 (1994).
71. West WH, Tauer KW, Yannelli JR et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316(15), 898-905 (1987).
72. West WH. Clinical application of continuous infusion of recombinant interleukin-2. Eur. J. Cancer Clin. Oncol. 25(Suppl. 3), S11-S15 (1989).
73. West WH. Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies. Cancer Treat. Rev. 16(Suppl. A), 83-89 (1989).
74. Geertsen PF, Gore ME, Negrier S, Tourani JM, von der Maase H. Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br. J. Cancer 90(6), 1156-1162 (2004).
75. Lotze MT, Line BR, Mathisen DJ. The in vivo distribution of autologous human and murine lymphoid cells. J. Immunol. 125, 1487-1493 (1980).
76. Weber JS, Rosenberg SA. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 48(20), 5818-5824 (1988).
77. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res. 49(24 Pt 1), 7086-7092 (1989).
78. Itoh K, Shiiba K, Shimizu Y, Suzuki R, Kumagai K. Generation of activated killer (AK) cells by recombinant interleukin-2 (rIL-2) in collaboration with interferon-γ (IFN-γ). J. Immunol. 134(5), 3124-3129 (1985).
79. Masucci G, Ragnhammar P, Wersall P, Mellstedt H. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A). Cancer Immunol. Immunother. 31(4), 231-235 (1990).
80. Steger GG, Kaboo R, deKernion JB, Figlin R, Belldegrun A. The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma. Br J. Cancer 72(1), 101-107 (1995).
81. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J. Exp Med. 180(1), 83-93 (1994).
82. Szabolcs P, Moore MA, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J. Immunol. 154(11), 5851-5861 (1995).
83. Tamura T, Sasaki Y, Shinkai T et al. Phase I study of combination therapy with interleukin-2 and β-interferon in patients with advanced malignancy. Cancer Res. 49(3), 730-735 (1989).
84. Paolozzi F, Zamkoff K, Doyle M et al. Phase I trial of recombinant interleukin-2 and recombinant β-interferon in refractory neoplastic diseases. J. Biol. Response Mod. 8(2), 122-139 (1989).
85. 2a in cancer patients: a Phase I study. J. Clin. Oncol. 7(11), 1726-1732 (1989).
86. Budd GT, Osgood B, Barna B et al. Phase I clinical trial of interleukin-2 and α-interferon: toxicity and immunologic effects. Cancer Res. 49(22), 6432-6436 (1989).
87. 2a: clinical effects. J. Biol. Response Mod. 9(6), 538-545 (1990).
88. Mittelman A, Huberman M, Puccio C et al. A Phase I study of recombinant human interleukin-2 and α-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma Cancer 66(4), 664-669 (1990).
89. 2a as out-patient therapy for patients with advanced malignancy. J. Clin. Oncol. 8(10), 1657-1663 (1990).
90. 2a-interferon in patients with solid tumors. Cancer 68(8), 1708-1713 (1991).
91. 2a-interferon combination in advanced malignancies. Ann. Oncol. 3(7), 559-563 (1992).
92. 2a. Cancer 71(7), 2371-2376 (1993).
93. 2a and interleukin-2 for the treatment of metastatic cancer. J. Clin. Oncol. 13(5), 1110-1122 (1995).
94. 2a in patients with advanced cancer. J. Clin. Oncol. 14(8), 2234-2241 (1996).
95. Atzpodien J, Kirchner H, de Mulder P et al. Subcutaneous recombinant interleukin-2 and α-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study. Cancer Biother. 8(4), 289-300 (1993).
96. 2a in progressive metastatic renal cell carcinoma. J. Clin. Oncol. 13(2), 497-501 (1995).
97. 2a in advanced renal cell carcinoma: a confirmatory study. Br. J. Cancer 72(6), 1531-1535 (1995).
98. Clark JI, Gaynor ER, Martone et al. Daily subcutaneous ultra-low-dose interleukin-2 with daily low-dose interferon-α in patients with advanced renal cell carcinoma. Clin. Cancer Res. 5(9), 2374-2380 (1999).
99. 2b in advanced renal cell carcinoma: long-term results. Cancer Detect Prev. 23(2), 172-176 (1999).
100. Schmidinger M, Steger GG, Wenzel C et al. Sequential administration of interferon-γ and interleukin-2 in metastatic renal cell carcinoma: results of a Phase II trial. Austrian Renal Cell Carcinoma Study Group. Cancer Immunol. Immunother. 49(7), 395-400 (2000).
101. Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two Phase II clinical trials. Cancer 88(6), 1317-1324 (2000).
102. Rogers E, Bredin H, Butler M et al. Combined subcutaneous recombinant α-interferon and interleukin-2 in metastatic renal cell cancer: results of the Multicentre All Ireland Immunotherapy Study Group. Eur. Urol. 37(3), 261-266 (2000).
103. Hotton KM, Khorsand M, Hank JA et al. A Phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis. Cancer 88(8), 1892-1901 (2000).
104. Schmidinger M, Steger G, Wenzel C et al. Sequential administration of interferon-γ, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial. J. Immunother. 24(3), 257-262(2001).
105. Buzio C, Andrulli S, Santi R et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-α in the treatment of patients with advanced renal cell carcinoma. Cancer 92(9), 2286-2296 (2001).
106. Ravaud A, Delva R, Gomez F et al. Subcutaneous interleukin-2 and interferon-α in the treatment of patients with metastatic renal cell carcinoma. Less efficacy compared with intravenous interleukin-2 and interferon-α. Results of a multicenter Phase II trial from the Groupe Francais d'Immunotherapie. Cancer 95(11), 2324-2330 (2002).
107. 2a in advanced renal cell carcinoma: major durable responses in a less highly selected patient population. Ann. Oncol. 13(4), 606-613 (2002).
108. Tourani JM, Pfister C, Tubiana N et al. Subcutaneous interleukin-2 and interferon-α administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, Phase II, nonrandomized study with sequential analysis design-the Subcutaneous Administration Propeukin Program Co-operative Group. J. Clin. Oncol. 21(21), 3987-3994 (2003)
109. Verra N, Jansen R, Groenewegen G et al. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma. Br. J. Cancer 88(9), 1346-1351 (2003).
110. Palmer PA, Atzpodien J, Philip T et al. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon-α in patients with advanced renal cell carcinoma. Cancer Biother. 8(2), 123-136 (1993).
111. 2a in advanced renal cell carcinoma. J. Clin. Oncol. 11(4), 661-670 (1993).
112. Lissoni P, Barni S, Ardizzoia A et al. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-α as first line therapy for metastatic renal cell carcinoma. Tumori 79(6), 397-400 (1993).
113. Witte RS, Leong T, Ernstoff MS et al. A Phase II study of interleukin-2 with and without β-interferon in the treatment of advanced renal cell carcinoma. Invest. New Drugs. 13(3), 241-247 (1995).
114. 2a in metastatic renal cell carcinoma. J. Urol. 155(2), 455-458 (1996).
115. Boccardo F, Rubagotti A, Canobbio L et al. Interleukin-2, interferon-α and interleukin-2 plus interferon-α in renal cell carcinoma. A randomized Phase II trial. Tumori. 84(5), 534-539 (1998).
116. 2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl J. Med. 338(18), 1272-1278 (1998).
117. Lissoni P, Mengo S, Bucovec R et al. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients. In vivo. 17(1), 73-75 (2003).
118. Smith JW II, Kurt RA, Baher AG et al. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, in-patient interleukin-2 regimen: a randomized Phase I trial in patients with metastatic melanoma and renal cell carcinoma. J. Immunother. 26(2), 130-138 (2003).
119. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancer. Eur. J. Cancer 29A(Suppl. 5) S6-S8 (1993).
120. Atzpodien J, Kirchner H, Duensing S et al. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, α-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J. Urol. 13(3 , 174-177 (1995).
121. Joffe JK, Banks RE, Forbes MA et al. A Phase II study of interferon-α, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br. J. Urol. 77(5), 638-649 (1996).
122. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HG. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J. Urol. 156(1), 18-21 (1996).
123. Lopez Hanninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol. 155(1), 19-25 (1996).
124. Hofmockel G, Theiss M, Gruss A, Langer W, Frohmuller H. Immunochemotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-α and 5-fluorouracil. Urologe A 36(1), 45-49 (1997).
125. Ellerhorst JA, Sella A, Amato RJ et al. Phase II trial of 5-fluorouracil, interferon-α and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80(11), 2128-2132 (1997).
126. Tourani JM, Pfister C, Berdah JF et al. Out-patient treatment with subcutaneous interleukin-2 and interferon-α administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized Phase II study. Subcutaneous Administration Propeukin Program Co-operative Group. J. Clin. Oncol. 16(7), 2505-2513 (1998).
127. 2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter Phase II trial. Groupe Francais d'Immunotherapie. J. Clin. Oncol. 16(8 ), 2728-2732 (1998).
128. 2a and 5-fluorouracil in the treatment of metastatic renal cell cancer. Eur. Urol. 35(3), 204-209 (1999).
129. Elias L, Binder M, Mangalik A et al. Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-α for advanced renal cell carcinoma. Am. J. Clin. Oncol. 22(2), 156-161 (1999).
130. Elias L, Lew D, Figlin RA et al. Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma: a Southwest Oncology Group Phase II study. Cancer 89(3), 597-603 (2000).
131. van Herpen CM, Jansen RL, Kruit WH et al. Immunochemotherapy with interleukin-2, interferon-α and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter Phase II study. Dutch Immunotherapy Working Party. Br. J. Cancer 82(4), 772-776 (2000).
132. Allen MJ, Vaughan M, Webb A et al. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and α-interferon in patients with metastatic renal cell cancer: a Phase II study. Br. J. Cancer 83(8), 980-985 (2000).
133. Dutcher JP, Logan T, Gordon M et al. Phase II trial of interleukin-2, interferon α, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin. Cancer Res. 6(9), 3442-3450 (2000).
134. 2a, and fluorouracil in patients with metastatic renal carcinoma. J. Cancer Res. Clin. Oncol. 127(5), 319-324 (2001).
135. Soori G, Dillman RO, Wiemann MC et al. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-α, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10. Cancer Biother. Radiopharm. 17(2), 165-173 (2002).
136. Ryan CW, Vogelzang NJ, Stadler WM. A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma. Cancer 94(10), 2602-2609 (2002).
137. Gez E, Rubinov R, Gaitini D et al. Interleukin-2, interferon-α, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective Phase II study: the experience of Rambam and Lin Medical Centers 1996-2000. Cancer 95(8), 1644-1649 (2002).
138. Roigas J, Deger S, Taymoorian K et al. Effects of 13- cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma-results of a retrospective analysis. Cancer Biother. Radiopharm. 18(2), 157-163 (2003).
139. 2a and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a Phase II trial. Br. J. Cancer 89(12), 2213-2218 (2003).
140. Rathmell WK, Malkowicz SB, Holroyde C, Luginbuhl W, Vaughn DJ. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-α and interleukin-2 for advanced renal cell cancer. Am. J. Clin. Oncol. 27(2), 109-112 (2004).
141. Indrova M, Bubenik J, Jakoubkova J et al. Subcutaneous interleukin-2 in combination with vinblastine for metastatic renal cancer: cytolytic activity of peripheral blood lymphocytes. Neoplasma 41(4), 197-200 (1994).
142. 2b in combination with intravenous vinblastine in metastatic renal cell cancer. Oncology 55(1), 10-15 (1998).
143. Gez E, Mekori T, Struminger L et al. T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interferon-α, 5-fluorouracil, and vinblastine. Cancer Invest. 17(4), 259-263 (1999).
144. Lindemann A, Hoeffken K, Schmidt RE et al. A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies. Cancer Treat. Rev. 16(Suppl. A), 53-57 (1989).
145. Buter J, Janssen RA, Martens A, Sleijfer DT, de Leij L, Mulder NH. Phase I/II study of low-dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer. Eur. J. Cancer 29A(15), 2108-2113 (1993).
146. Mertens WC, Bramwell VH, Banerjee D et al. Sustained oral indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced renal cell carcinoma. Cancer Biother. 8(3), 229-233 (1993).
147. Wersall JP, Masucci G, Hjelm AL et al. Low dose cyclophosphamide, α-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma. Med. Oncol. Tumor Pharmacother. 10(3), 103-111 (1993).
148. Deckert M, Franzke A, Buer J et al. Linomide and interleukin-2 in patients with advanced renal cell carcinoma. Cancer Biother Radiopharm. 11(5), 319-324 (1996).
149. Stadler WM, Kuzel T, Dumas M, Vogelzang NJ. Multicenter Phase II trial of interleukin-2, interferon-α, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J. Clin. Oncol. 16(5), 1820-1825 (1998).
150. Creagan ET, Hestorff RD, Suman VJ et al. Combined
151. Lissoni P, Rovelli F, Baiocco N, Tingini G, Fumagalli L. A Phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone. Anticancer Res. 21(1B), 777-779 (2001).
152. Donskov F, von der Maase H, Henriksson R et al. Out-patient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre Phase II study. Ann. Oncol. 13(3), 441-449 (2002).
153. Naglieri E, Lopez M, Lelli G et al. Interleukin-2, interferon-α and medroxyprogesterone acetate in metastatic renal cell carcinoma. Anticancer Res. 22(5), 3045-3051 (2002).
154. Lissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone. Neuro. Endocrinol. Lett. 23(3), 255-258 (2002).
155. Neri B, Doni L, Gemelli MT et al. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer. J. Urol. 168(3), 956-958(2002).
156. Kedar I, Mermershtain W, Ivgi H. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int. J. Cancer 110(2), 260-265 (2004).
157. Hrushesky WJ, Murphy GP. Current status of the therapy of advanced renal cell carcinoma. J. Surg. Oncol. 277-288 (1977).
158. Blay JY, Negrier S, Combaret V et al. Serum level of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 52(12), 3317-3322 (1992).
159. Witte RS, Leong T, Ernstoff MS et al. A Phase II study of interleukin-2 with and without β-interferon in the treatment of advanced renal cell carcinoma. Invest. New Drugs 13(3), 241-247 (1995).
160. Takahashi A, Sasaki H, Kim SJ et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor inrenal cell carcinoma associated with angiogenesis. Cancer Res. 54, 4233-4237 (1994).
161. Bonfanti A, Lissoni P, Bucovec R, Rovelli F, Brivio F, Fumagalli L. Changes in circulating dendritic cells and IL-12 in relation to the angiogenic Factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer. Int. J. Biol. Markers 15(2), 161-164 (2000).
162. Lissoni P, Bolis S, Brivio F, Fumagalli L. A Phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Anticancer Res. 20(3B), 2103-2105 (2000).
163. Lissoni P, Barni S, Tancini G et al. Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapy. Tumori 79(4), 246-249 (1993 ).
164. Henriksson R, Nilsson S, Colleen S et al. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs. interleukin-2, α-interferon (leucocyte) and tamoxifen. Br J. Cancer 77(8), 1311-1317 (1998).
165. Naglieri E, Gebbia V, Durini E et al. Standard interleukin-2 (IL-2) and interferon-α immunotherapy versus an IL-2 and 4-epirubicin immunochemotherapeutic association in metastatic renal cell carcinoma. Anticancer Res. 18(3B), 2021-2026 (1998).
166. 2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Co-operative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J. Clin. Oncol. 22(7), 1188-1194 (2004).
167. Negrier S, Caty A, Lesimple T et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon-α with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J. Clin. Oncol. 18(24), 4009-4015 (2000).
168. Atzpodien J, Kirchner H, Illiger HJ et al. IL-2 in combination with IFN α and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J. Cancer 85(8), 1130-1136 (2001).
169. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22(3), 454-463(2004).
170. Koretz MJ, Lawson DH, York RM et al. Randomized study of interleukin-2 (IL-2) alone vs. IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. Arch. Surg. 126(7), 898-903(1991).
171. Weiss GR, Margolin KA, Aronson FR et al. A randomized Phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. Arch. Surg. 126(7), 898-903 (1991).
172. Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. 85(8), 622-632(1993).
173. Law TM, Motzer RJ, Mazumdar M et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76(5), 824-832 (1995).
174. Fenton RG, Steis RG, Madara K et al. A Phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma. J. Immunother. Emphasis Tumor Immunol. 19(5), 364-374 (1996).
175. Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, Phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J. Clin. Oncol. 17(8), 2521-2529(1999).
176. Clark JI, Atkins MB, Urba WJ et al. Adjuvant high-dose bolus interleukin-2 for patients with high risk renal cell carcinoma - a Cytokine Working Group randomized trial. J. Clin. Oncol. 21, 3133-3140 (2003).
177. Donskov F, Bennedsgaard KM, Von der Maase H et al. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br. J. Cancer 87(2), 194-201(2002).
178. Atkins M, McDermott D, Regan M et al. Carbonic Anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. Proc. Am. Soc. Clin. Oncol. Ann. (2004) (Abstract 4512).
179. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349(5), 427-434 (2003).